Ichor (NASDAQ:ICHR – Get Free Report) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.210-0.330 for the period, compared to the consensus estimate of 0.210. The company issued revenue guidance of $220.0 million-$235.0 million, compared to the consensus revenue estimate of $216.2 million. Ichor also updated its Q4 guidance to $0.21-0.33 EPS.
Ichor Trading Down 0.8 %
Shares of ICHR stock traded down $0.21 during trading on Monday, hitting $27.14. 242,758 shares of the stock traded hands, compared to its average volume of 305,310. Ichor has a 52-week low of $22.26 and a 52-week high of $46.43. The firm has a market capitalization of $914.35 million, a P/E ratio of -22.43 and a beta of 1.91. The firm’s fifty day moving average price is $28.95 and its 200-day moving average price is $33.87. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.27 and a quick ratio of 1.91.
Ichor (NASDAQ:ICHR – Get Free Report) last posted its earnings results on Tuesday, August 6th. The technology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The company had revenue of $203.23 million for the quarter, compared to the consensus estimate of $197.75 million. Ichor had a negative return on equity of 2.56% and a negative net margin of 4.53%. As a group, research analysts forecast that Ichor will post -0.17 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on ICHR
About Ichor
Ichor Holdings, Ltd. engages in the design, engineering, and manufacture of fluid delivery subsystems and components for semiconductor capital equipment in the United States and internationally. It primarily offers gas and chemical delivery systems and subsystems that are used in the manufacturing of semiconductor devices.
Read More
- Five stocks we like better than Ichor
- CD Calculator: Certificate of Deposit Calculator
- Intel: Is Now the Time to Be Brave?Â
- Most Volatile Stocks, What Investors Need to Know
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Ichor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ichor and related companies with MarketBeat.com's FREE daily email newsletter.